These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36128643)

  • 1. An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction.
    Yang H; Li R; Ma F; Wei Y; Liu Y; Sun Y; He X; Zeng H; Yan J; Wang DW; Wang H
    ESC Heart Fail; 2022 Dec; 9(6):4280-4290. PubMed ID: 36128643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    Davies DR; Redfield MM; Scott CG; Minamisawa M; Grogan M; Dispenzieri A; Chareonthaitawee P; Shah AM; Shah SJ; Wehbe RM; Solomon SD; Reddy YNV; Borlaug BA; AbouEzzeddine OF
    JAMA Cardiol; 2022 Oct; 7(10):1036-1044. PubMed ID: 36069809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac amyloidosis: a significant blind spot of the H2FPEF score.
    Duca F; Rettl R; Binder C; Dusik F; Schrutka L; Dalos D; Öztürk B; Capelle CD; Qin H; Dachs TM; Camuz Ligios L; Agis H; Kain R; Hengstenberg C; Badr-Eslam R; Kastner J; Bonderman D
    Panminerva Med; 2023 Dec; 65(4):491-498. PubMed ID: 36789997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
    Castaño A; Narotsky DL; Hamid N; Khalique OK; Morgenstern R; DeLuca A; Rubin J; Chiuzan C; Nazif T; Vahl T; George I; Kodali S; Leon MB; Hahn R; Bokhari S; Maurer MS
    Eur Heart J; 2017 Oct; 38(38):2879-2887. PubMed ID: 29019612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis.
    Cuddy SA; Datar Y; Ovsak G; Saith S; Murphy SP; Bay CP; Haddad M; Lilleness B; Muralidhar V; Pipilas A; Vuong J; Guardino E; Maurer MS; Ruberg FL; Falk RH; Dorbala S
    Circ Cardiovasc Imaging; 2022 Nov; 15(11):e014645. PubMed ID: 36378779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
    García-Pavía P; García-Pinilla JM; Lozano-Bahamonde A; Yun S; García-Quintana A; Gavira-Gómez JJ; Aibar-Arregui MÁ; Barge-Caballero G; Núñez Villota J; Bernal L; Tarilonte P
    Rev Esp Cardiol (Engl Ed); 2024 Jul; ():. PubMed ID: 39089574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis.
    Bonfioli GB; Tomasoni D; Vergaro G; Castiglione V; Adamo M; Fabiani I; Loghin V; Lombardi CM; Nicolai A; Metra M; Emdin M; Aimo A
    Eur J Heart Fail; 2024 Sep; ():. PubMed ID: 39252401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.
    Hahn VS; Yanek LR; Vaishnav J; Ying W; Vaidya D; Lee YZJ; Riley SJ; Subramanya V; Brown EE; Hopkins CD; Ononogbu S; Perzel Mandell K; Halushka MK; Steenbergen C; Rosenberg AZ; Tedford RJ; Judge DP; Shah SJ; Russell SD; Kass DA; Sharma K
    JACC Heart Fail; 2020 Sep; 8(9):712-724. PubMed ID: 32653448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence of transthyretin cardiac amyloidosis in patients hospitalized for heart failure with preserved ejection fraction and septal thickness].
    Decotto S; Fernández Villar G; Llamedo MC; Villanueva E; Pérez De Arenaza D; Lucas L; Del Castillo S; Rossi E; Belziti C; Pizarro R
    Medicina (B Aires); 2024; 84(5):823-830. PubMed ID: 39399922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
    Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
    ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A challenging road to diagnosing transthyretin cardiac amyloidosis and using technetium-99m pyrophosphate bone scintigraphy in nuclear cardiology - A case report.
    Kavita A; Abdul Onny MA; Suppiah S; Abdul Aziz AF; Hashim H; Raja Shariff RE; Ng CS
    Med J Malaysia; 2021 Sep; 76(5):762-767. PubMed ID: 34508392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.
    Lo Presti S; Horvath SA; Mihos CG; Rajadhyaksha C; McCloskey V; Santana O
    Crit Pathw Cardiol; 2019 Dec; 18(4):195-199. PubMed ID: 31725511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.
    Bennani Smires Y; Victor G; Ribes D; Berry M; Cognet T; Méjean S; Huart A; Roussel M; Petermann A; Roncalli J; Carrié D; Rousseau H; Berry I; Chauveau D; Galinier M; Lairez O
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1403-1413. PubMed ID: 27240600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
    Klaassen SH; van Veldhuisen DJ; Nienhuis H; van den Berg MP; Hazenberg BP; van der Meer P
    Card Fail Rev; 2020 Mar; 6():e21. PubMed ID: 32944291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
    Smiley DA; Rodriguez CM; Maurer MS
    Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction.
    Yalvaç HE; Murat S; Ak Sivrikoz İ; Üsküdar Teke H; Çilingir O; Çolak E; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2024 Jun; 52(4):227-236. PubMed ID: 38829635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis.
    Alonso M; Neicheril RK; Manla Y; McDonald ML; Sanchez A; Lafave G; Seijo De Armas Y; Camargo AL; Uppal D; Wolinsky D; Thakkar-Rivera N; Velez M; Baran DA; Estep JD; Snipelisky D
    ESC Heart Fail; 2024 Aug; ():. PubMed ID: 39180423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.